Management of Intermediate-Risk MDS
In this podcast, Dr. Brian C. Shaffer and Dr. Linda Burns discuss a case study highlighting several factors facing both leukemia and transplant specialists in the management of patients with intermediate-risk myelodysplastic syndromes (MDS).
Hematologists, oncologists, nurse practitioners, physician assistants, and other health care professionals who treat patients with MDS.
Identify key clinical factors from new molecular genetic study results that provide prognostic information that can be used to guide treatment decisions for patients with intermediate and high risk MDS.
Brian C. Shaffer, M.D.
Memorial Sloan Kettering Cancer Center
Linda J. Burns, M.D.
National Marrow Donor Program/ Be the Match
If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email email@example.com.
The information contained in this a podcast is for the general purpose of providing information about myelodysplastic syndromes. The case study article and podcast are not intended in any way shape or form to constitute, nor should it be considered, medical advice, treatment, or diagnosis. The National Marrow Donor Program/Be The Match does not recommend or endorse any specific treatment, physicians, references, or opinions and disclaims any representation, warranty, or guaranty as to the same. Please consult with a physician or other healthcare professional regarding any medical or health related questions, or diagnosis and treatment options.